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nmol/min) in CBDL rats corrected both the impaired natri-Increased cGMP phosphodiesterase activity mediates renal re-
uretic response to VE and the blunted VE-related increase insistance to ANP in rats with bile duct ligation.
urinary cGMP excretion from the infused, but not the contralat-Background. Liver disease resulting from common bile duct
eral kidney.ligation (CBDL) causes abnormal sodium metabolism that is
Conclusion. These results demonstrate that renal resistancemanifested by resistance to the natriuretic action of atrial natri-
to ANP in CBDL rats is accompanied by heightened activityuretic peptide (ANP). This resistance is corrected both in vitro
of PDE5, which is due largely to an increase in PDE5 protein.and in vivo by zaprinast, a selective inhibitor of a guanosine
Other PDEs could contribute only a minor part to the enhancedcyclic-39-59-monophosphate (cGMP)-specific phosphodiester-
cGMP hydrolysis observed in kidneys of CBDL rats. This PDE5-ase (PDE5). Several other PDEs with affinity for cGMP are
dependent ANP resistance may represent an important con-expressed in kidney and could also be involved in this response.
tributor to the sodium retention of liver disease.Methods. We measured cGMP hydrolysis in inner medullary
collecting duct (IMCD) cell homogenates from kidneys of
sham-operated and CBDL rats and quantitated the amount of
PDE5 protein by Western blotting and immunoprecipitation Sodium retention with the formation of ascites andstudies. We also characterized ANP responsiveness in vivo of
edema is a hallmark of chronic liver disease and is associ-kidneys of anesthetized sham and CBDL rats by measuring
ated with resistance to the renal actions of atrial natri-sodium excretion before and after volume expansion (VE).
Results. Kinetic analysis of PDE5 activity in homogenates uretic peptide (ANP) [1]. The basis for this resistance is
of IMCD cells isolated from kidneys of sham-operated rats not established. Recently, we suggested that ANP resis-
indicated a Vmax of 85.3 6 1.7 versus 157 6 2.9 pmol/mg/min tance in experimental nephrotic syndrome and in rats
from CBDL rats (P , 0.01), without a difference in Km. Enzyme with common bile duct ligation (CBDL) could resultactivity was inhibited competitively by 1,3-dimethyl-6-(2-pro-
from increased activity of a guanosine 39,59-cyclic mono-poxy-5-methanesulfonylamidophenyl)pyrazol[3,4d]-pyrimi-
phosphate (cGMP)-specific phosphodiesterase (PDE5)din-4-(5H)-one (DMPPO), a potent and specific inhibitor of
PDE5, with an apparent Ki of 4.5 6 0.7 and 4.9 6 0.7 nmol/L [2–4]. This increased activity rapidly catabolizes the in-
and an IC50 of 6.1 6 0.8 and 8.7 6 0.7 nmol/L in sham and tracellular second messenger cGMP, which is normally
CBDL rats, respectively (P 5 NS). DMPPO exhibited very formed when ANP binds to its biologically active recep-poor inhibitory activity against the calcium-calmodulin–
tors. The basis for this suggestion was the observationdependent PDE1 in IMCD homogenates from sham rats (Ki
that the selective PDE5 inhibitor zaprinast corrected1.3 6 0.1 mmol/L and IC50 1.9 6 0.2 mmol/L). Western analysis
using an antiserum made against bovine lung PDE5 revealed manifestations of ANP resistance both in vivo and in
a twofold increase in PDE5 protein in cytosolic extracts from vitro [2–4]. Most tissues contain multiple isozymes of
IMCD of CBDL rat kidneys compared with sham-operated PDE, of which several found in renal tissue have highcontrols, and immunoprecipitation studies indicated that the
affinity for cGMP. These include the calcium-calmodu-increase in PDE5 protein accounted for the observed increase
lin–dependent PDE1, the cGMP-specific PDE5 [5–9],in cGMP hydrolysis. DMPPO (10 nmol/L) normalized the
blunted ANP-dependent cGMP accumulation by IMCD cells and the recently described PDE9 [10–12], PDE10 [13],
from CBDL rats in vitro. Intrarenal infusion of DMPPO (0.5 and PDE11 [14]. In vascular smooth muscle, pharmaco-
logic studies have suggested that both the calcium-cal-
modulin–stimulated PDE1 and PDE5 mediate catabo-Key words: chronic liver disease, atrial natriuretic peptide, GMP-spe-
lism of cGMP stimulated by ANP [9, 15], whereas incific phosphodiesterase, inner medullary collecting duct, sodium excre-
tion. cultured inner medullary collecting duct (IMCD) cells,
PDE1 appeared responsible for hydrolysis of ANP-stim-Received for publication August 9, 2000
ulated cGMP [6]. Currently, no information is availableand in revised form October 18, 2000
Accepted for publication October 23, 2000 about renal cell types expressing PDE9, PDE10, or PDE11
or their roles in determining hormone responsiveness.Ó 2001 by the International Society of Nephrology
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In the present study, we characterized cGMP hydrolysis tions were averaged and expressed as femtomoles accu-
mulated per 10-minute incubation per milligram protein.in IMCD cells from sham-operated rats and rats 7 to 10
days after CBDL using DMPPO, a novel, potent, and PDE assays. Immediately after isolation, as just de-
scribed, IMCD cells were homogenized in a glass-Teflonspecific inhibitor of PDE5 [16, 17], to explore the role
of PDE5 activity in the renal ANP resistance that occurs homogenizer. The homogenizing medium had the fol-
lowing composition (mmol/L): sucrose, 250; Tris, 10;in CBDL rats. We also used a polyclonal antiserum to
PDE5 to quantitate enzyme protein in cytosol of IMCD 2-(morpholino) ethanesulfonic acid, 10; MgC12, 5; ethyl-
enediaminetetraacetic acid (EDTA), 1; egtazic acidcells from kidneys of sham-operated and CBDL rats.
(EGTA), 1; and mercaptoethanol, 5, pH 7.4. The solu-
tion also contained 0.1 mmol/L phenylmethylsulfonyl
METHODS
fluoride (PMSF), 0.1 mmol/L leupeptin, and 0.1 mmol/L
We used adult male Sprague-Dawley rats weighing pepstatin. Homogenization (1:3 wet wt/vol) and all other
250 to 300 g that were allowed free access to a normal preparative procedures were conducted at 48C. The ho-
sodium content, rat pellet diet, and tap water. All experi- mogenate was centrifuged for 60 minutes at 100,000 3
mental procedures were reviewed and approved by the g, and the supernatant was used for the PDE assays.
Committee on Animal Research of the University of The PDE5 assay (total volume 125 mL) was modified
California San Francisco. Rats were anesthetized with from Turko, Francis, and Corbin [19]. The incuba-
methohexital sodium (50 mg/kg intraperitoneally). The tion mixture contained (mmol/L) the following: MOPS,
abdomen was opened in the midline, and the common 40 (pH 7.5); EGTA 0.8; magnesium acetate 15; and
bile duct was identified. The duct was cut between double 0.5 mmol/L [3H]-cGMP (specific activity 444 GBq/mmol)
ligatures, and the abdominal wound was closed. Sham and 0.2 mg/mL bovine serum albumin (BSA). The PDE
rats underwent the same surgical procedure but without activity in aliquots incubated without Ca21 and calmodu-
CBDL. The rats were returned to the vivarium and al- lin was determined as basal PDE5 activity [20]. Reactions
lowed to recover for 7 to 10 days. were started by the addition of 25 mL of the diluted
enzyme preparations, followed by incubation for 15 min-
In vitro studies
utes at 308C. The reaction was stopped by heating at
ANP-dependent cGMP accumulation in IMCD cells. 958C for three minutes. After cooling, 10 mL of a solution
IMCD cells from rat kidneys were isolated by collage- of 10 mg/mL nucleotidase as crotalus atox venom were
nase digestion according to the method of Zeidel et al added followed by a 20-minute incubation at 308C. Nu-
[18] as performed in our laboratory [2–4]. Aliquots of cleoside products were separated from unreacted nucleo-
freshly prepared IMCD cells were suspended in 350 mL tides using a DEAE Sephadex A-25 column equilibrated
of buffer containing (mmol/L) the following: NaCl, 124; with 20 mmol/L Tris-HCl buffer, pH 6.8, and the column
KCl, 5; CaCl2, 1; MgSO4, 0.4; Na2HPO4, 1; N-hydroethyl- effluent was counted for [3H] activity in a liquid scintilla-
piperazine-N1-2 ethanesulfonic acid (HEPES), 50; and tion counter (Packard Instruments, Chicago, IL, USA).
glucose, 7.5. Cells were preincubated for 10 minutes at For examining the activity of Ca21-calmodulin–depen-
378C in a shaking water bath. In some preparations, dent PDE1, EGTA was replaced by 10 mmol/L CaCl2
the PDE5 inhibitors DMPPO or zaprinast at different and 20 nmol/L calmodulin. Vmax and Km values were
concentrations were included. Incubation was started by determined from Lineweaver-Burke plots after assaying
adding synthetic ANP (Peninsula Laboratories, Bel- cGMP hydrolysis in duplicate over a range of cGMP
mont, CA, USA) at a concentration of 1029 to 1026 mol/L concentrations from 0.44 to 8.0 mmol/L. Ki values for
and terminated after 10 minutes by adding 750 mL of ice- the PDE inhibitors were obtained from Dixon plots. IC50
cold trichloroacetic acid (TCA). The precipitated protein values for DMPPO or zaprinast were determined from
was sedimented by centrifugation, and the pellet was concentration-response curves; the concentration of
dissolved in 1 N NaOH and assayed for protein concen- DMPPO ranged from 1 to 30 nmol/L, while the concen-
tration by the Bradford dye-binding method (Bio-Rad tration of zaprinast ranged from 0.03 to 1 mmol/L for
Laboratories, Hercules, CA, USA). The supernatant PDE5 and from 0.3 to 1 mmol/L for PDE1.
fluid was extracted four times with five volumes of water- Immunoblotting. We measured PDE5 protein content
saturated ethyl ether to remove the TCA before being in kidneys of sham and CBDL rats. Kidneys were divided
evaporated to dryness under a stream of air and stored into cortex and medulla; the cortex was diced into small
at 2808C until assayed for cGMP content. For the cGMP pieces with a razor, while medulla was processed for
assay, samples were dissolved in 50 mmol/L sodium ace- IMCD cells as described previously in this article. The
tate buffer, pH 6.2, and 100 mL aliquots were assayed cortical tissue fragments and IMCD cells were added to
with a commercial kit (New England Nuclear, Boston, cold lysis buffer [3 mL/g tissue of RIPA buffer; Santa
MA, USA) following acetylation according to the manu- Cruz Biotechnologies, Santa Cruz, CA, USA; containing
1 3 phosphate-buffered saline (PBS), 1% igepal CA-630;facturer’s instructions. Results of duplicate determina-
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Sigma, St. Louis, MO, USA; 0.5% sodium deoxycholate,
and 0.1% sodium dodecyl sulfate (SDS) to which we
added 100 mg/mL PMSF and 45 mg/mL aprotinin]. The
suspension was homogenized using a polytron at 08C
and centrifuged at 10,000 3 g at 48C for 10 minutes. The
supernatant was recentrifuged, and the second superna-
tant was measured for protein content using the dye-
binding method of Bradford (Bio-Rad Laboratories) and
stored at 2208C. Aliquots (40 mg protein) were size
fractionated on precast 4 to 20% gradient SDS-poly-
acrylamide gels in an Amersham SE 280 vertical gel
electrophoresis unit at 40 mA for one hour and electro-
transferred to nitrocellulose membranes. These mem-
branes were then blocked with 5% dried milk in PBS,
pH 7.5, containing 0.1% Tween for one hour at room
temperature, rinsed, and incubated for one hour with
the primary antiserum, raised against bovine lung PDE5
(Chemicon International Inc., Temecula, CA, USA) at
a dilution of 1:1000 [21]. Bound antibody was visualized
using horseradish peroxidase-conjugated donkey anti- Fig. 1. Atrial natriuretic peptide (ANP)-dependent cGMP accumula-
rabbit secondary antibody, diluted 1:1000, for 30 minutes tion by inner medullary collecting duct (IMCD) cells isolated from
kidneys of sham (d) or common bile duct-ligated (CBDL; s) rats.(RPN 2108 ECL kit; Amersham, Arlington Heights, IL,
Values are means 6 SE of measurements in five preparations in eachUSA); the chemiluminescent signal was detected on group. Cells from CBDL rats exhibited decreased accumulation in con-
x-ray film and quantitated by densitometric scanning. trol (C) and at every concentration of ANP studied. *Significantly
greater than control, P , 0.05; †significant difference between shamImmunoprecipitation. Cytosolic fractions of IMCD
and CBDL, P , 0.05.cells from sham-operated and CBDL rat kidneys were
incubated with the antiserum against bovine lung PDE5
described previously in this article or with preimmune
serum, using a modification of the technique of Iona et at 2.4 mL/hour. After one hour of equilibration, a blood
sample (100 mL) was obtained, and urine was collectedal [22]. The antiserum was used in dilutions of 1:1000,
1:100, or 1:10, while the preimmune serum was used at for three 10-minute intervals. Over five minutes, normal
saline was then given intravenously in an amount equala dilution of 1:10. Incubation took place at 48C for one
hour with continuous mixing. The resulting antigen-anti- to 2% of the rat’s body weight to produce acute volume
expansion (VE). Urine samples were obtained for threebody complexes were precipitated by incubation with
protein A-agarose (Santa Cruz Biotechnologies), diluted successive 10-minute periods after VE. A large blood
sample was then harvested into a chilled Vacutainer tube1:50, for one hour at 48C, followed by centrifugation at
14,000 3 g at 48C for five minutes. The supernatant was (Becton-Dickinson Co., Rutherford, NJ, USA) con-
taining EDTA and 500 KIU aprotinin, and the animalremoved for subsequent assay of PDE5 activity; pellets
were washed and resuspended in the same homogeniza- was euthanized. The sample was immediately centri-
fuged at 48C, and the plasma was decanted and storedtion buffer, and aliquots were used for the PDE5 assay.
at 2808C until assayed for ANP concentration.
In vivo studies
Analytical and statistical methodsRats were anesthetized with Inactint (100 mg/kg intra-
peritoneally; Charles Lockwood Associates, Sturtevant, Urine flow rate was determined gravimetrically and
urine sodium concentration measured by flame photom-WI, USA) and fitted with catheters in the jugular vein
and carotid artery. Catheters were also introduced into etry (Model 943; Instrumentation Laboratories, Lexing-
ton, MA, USA); sodium excretion (UNaV) was calculatedthe ureters to collect urine from each kidney. The left
renal pedicle was exposed via a flank incision, and a as the product of the two. Urinary cGMP concentration
was determined in unextracted urine using a commer-curved 30-gauge needle attached to PE-10 tubing was
inserted into the left renal artery with the tip directed cially available kit (New England Nuclear). Before the
assay, samples were acetylated according to the manufac-toward the kidney. DMPPO 0.2 mg/min (0.5 nmol/min)
or zaprinast 10 mg/min (37 nmol/min) was infused using turer’s instructions. Plasma samples underwent extrac-
tion through SepPak C18 cartridges (Waters Associates,a motor-driven syringe pump (Harvard Apparatus Co.
Inc., Dover, MA, USA) in a volume of 7.5 mL/min. All Milford, MA, USA) as described [2–4]. Eluates were
lyophilized, reconstituted in assay buffer, and assayedrats received an intravenous infusion of normal saline
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Fig. 2. Effect of 1,3-dimethyl-6-(2-propoxy-
5-methanesulfonylamidophenyl)pyrazol[3,4d]-
pyrimidin-4-(5H)-one (DMPPO) or zaprinast
on ANP-dependent cGMP accumulation in
IMCD cells from kidneys of sham (h) or
CBDL ( ) rats. All experiments were carried
out in the presence of 1026 mol/L ANP. In
the absence of inhibitors, CBDL cells showed
significantly blunted cGMP accumulation
(bars at far left). The inhibitors increased ac-
cumulation so that at a DMPPO concentration
of 1028 mol/L and a zaprinast concentration
of 1026 mol/L, the difference between sham
and CBDL cells was no longer significant. Re-
sults are from five experiments in each group;
NS, not significant.
for plasma ANP concentration using a commercial kit determined the rate of cGMP hydrolysis in the presence
of substrate (cGMP) concentrations ranging from 0.44(Peninsula Laboratories, Inc., Belmont, CA, USA) as
to 8.0 mmol/L and with DMPPO concentrations from 1reported for our laboratory [4]. Experimental results are
to 30 nmol/L. The results are shown in Figure 3. Inexpressed as means 6 1 SEM. The t test for paired or
homogenates from sham-operated rats (Fig. 3A), theunpaired data was used to assess differences within and
double reciprocal plot yielded a Vmax of 85.3 6 1.7 pmol/between groups, respectively, and one-way and re-
mg/min, with a Km of 1.13 6 0.1 mmol/L. Incubation withpeated-measures analysis of variance (ANOVA) with
increasing concentrations of DMPPO led to progressivethe Bonferroni post hoc test were used for multiple com-
increases in Km without change in Vmax, a pattern charac-parisons among and within groups. A P value ,0.05 was
teristic of competitive enzyme inhibition; at 30 nmol/Ltaken to indicate a significant difference.
DMPPO, the apparent Km was increased to 8.9 6 1.2
Materials mmol/L (P , 0.01), while Vmax was unchanged. Similar
results occurred in IMCD homogenates from CBDL ratsAll compounds were purchased from Sigma Chemical
(Fig. 3B), where the control double reciprocal plot inCo. (St. Louis, MO, USA) except as noted.
the absence of DMPPO yielded a Vmax of 157 6 2.9 pmol/
mg/min (P , 0.01 vs. sham-operated value) and a Km of
RESULTS 0.98 6 0.1 mmol/L (P 5 NS vs. sham value). DMPPO
Accumulation of cGMP by isolated IMCD cells from again caused competitive inhibition of enzyme activity,
both sham-operated and CBDL rats increased dose de- with the apparent Km at 30 nmol/L DMPPO increased
pendently in response to added ANP (Fig. 1). However, to 9.8 6 1.3 mmol/L, while Vmax was unchanged. These
IMCD cells from kidneys of CBDL rats exhibited sig- data allowed calculation of the inhibition constant (Ki)
nificantly blunted cGMP accumulation compared with and IC50; the results are shown in Table 1. No difference
IMCD cells from sham rats under basal conditions and in inhibition characteristics of DMPPO on PDE5 activity
at all concentrations of ANP (P , 0.05), as we have shown was observed between sham and CBDL IMCD homoge-
previously [4]. The PDE5 inhibitors DMPPO 1028 mol/L nates. Similar results were obtained with zaprinast (Ta-
or zaprinast 1026 mol/L each restored the blunted ANP ble 1). Thus, ANP resistance in IMCD cells, a known
responsiveness in IMCD cells from CBDL rats (Fig. 2). target of ANP action in the kidney, is accompanied by
Because DMPPO and zaprinast are selective inhibitors increased PDE5 activity in rats with CBDL.
of PDE5 [9, 15, 16, 23], the results of these inhibitor Since zaprinast has been shown to have inhibitory
studies suggested that IMCD cells from kidneys of CBDL activity against PDE1 [16, 24], which also has an affinity
rats might possess increased PDE5 activity. Therefore, for cGMP as a substrate, we examined the effect of
we carried out a kinetic analysis of PDE5 activity and DMPPO and zaprinast on the inhibition of PDE1 activity
its sensitivity to inhibition by DMPPO in IMCD cell in IMCD cell homogenates from sham-operated rats.
The results are also presented in Table 1. Vmax deter-homogenates from sham and CBDL rat kidneys. We
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Fig. 3. Double reciprocal plots of a cGMP-
specific phosphodiesterase (PDE5) activity in
IMCD cell homogenates from sham (A) and
CBDL (B) rats. Assays were carried out in the
absence (control) or presence of the indicated
concentrations of DMPPO over a range of
cGMP concentrations from 0.44 to 8.0 mmol/L;
each point represents the mean 6 SE of deter-
minations in five separate homogenates. Lines
were drawn by least-squares analysis. Symbols
are: (d) control; (j) 1 nmol/L; (m) 3 nmol/L;
(.) 10 nmol/L; (r) 30 nmol/L.
Table 1. Inhibition characteristics of DMPPO and zaprinast on PDE1 and PDE5 activity in IMCD cell homogenates from sham and CBDL rats
DMPPO
ZaprinastPDE5
Sham CBDL PDE1 Sham PDE5 Sham PDE1 Sham
Vmax pmol/mg/min 85.361.7 157.0a 62.9 75.261.4 81.461.8 69.664.6
Ki nmol/L 4.560.7 4.961.2 1,3006100 3126124 4,4806653
IC50 mmol/L 6.160.8 5.060.7 1,9006200 463618.9 6,17561,062
Values are means 6 SE of measurements in five IMCD cell homogenates. Abbreviations are in the Appendix.
a P , 0.01 vs. sham
mined kinetically averaged 75.2 6 1.4 pmol/mg/min in els of the protein were increased significantly in cytosol
of IMCD cells from CBDL rat kidneys compared withthe DMPPO studies and 69.6 6 4.6 pmol/mg/min in the
zaprinast experiments. Although both agents could be the sham-operated controls. No difference in PDE5 pro-
tein abundance was detected in homogenates from renalshown to inhibit this enzyme activity, both Ki and IC50
were much higher; in the case of DMPPO, these values cortex. These results indicate that IMCD cells from
CBDL rats have an increase in PDE5 protein that may bewere more than two orders of magnitude greater than
for inhibition of PDE5. Consequently, the ability of low responsible for the increase in enzyme activity described
previously in this article (Fig. 3).concentrations of these compounds to restore ANP-
dependent cGMP accumulation in IMCD cells from kid- This increase in enzyme protein was directly related to
increased enzyme activity. We incubated IMCD cytosolneys of CBDL rats in vitro is not likely to be due to
inhibition of PDE1. from sham-operated and CBDL rat kidneys with preim-
mune serum or one of three different dilutions of antise-The increase in PDE5 activity in IMCD cells from
kidneys of CBDL rats could result from a greater amount rum to PDE5. Basal cytosolic PDE5 activity in this group
of experiments was again elevated in samples from CBDLof enzyme protein, from post-translational modification,
or from a combination of the two. To explore this ques- compared with sham rats (165.8 6 12.0 vs. 84.9 6 6.1
pmol/min/mg, N 5 5, P , 0.001) and was not alteredtion, we carried out Western blots of cytosol from both
IMCD cells and a crude cortical homogenate of kidneys after incubation with preimmune serum (172.2 6 9.3 and
82.2 6 5.3 pmol/min/mg, respectively; Table 2). Incuba-from sham and CBDL rats using a commercial antiserum
developed against bovine lung PDE5 [21]. The results tion of cytosol with the PDE5 antiserum followed by
precipitation with protein A-agarose led to a concentra-are shown in Figure 4. The PDE5 antiserum detected a
single protein of molecular weight of approximately tion-dependent reduction in PDE5 activity in samples
from both sham and CBDL rats; at the highest concentra-98 kD, the predicted size of rat PDE5 and indicating
that this antiserum, which was developed against bovine tion of antiserum (1:10 dilution), PDE5 activity was re-
duced to 13% of basal activity in samples from shamlung PDE5, is cross-reactive with rat kidney PDE5. Lev-
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Fig. 4. Immunoblot of PDE5 protein in corti-
cal and IMCD cell homogenates from kidneys
of sham-operated (h) or CBDL ( ) rats. A
representative blot is shown above the densi-
tometric scanning of blots from five individual
experiments. PDE5 protein abundance was
increased in IMCD cytosol from CBDL rat
kidneys compared with shams; no change was
detected in cortical homogenates.
Table 2. PDE5 activity in supernatants and pellets of IMCD cells taining the precipitated antigen-antibody complexes,
from sham and CBDL rat kidneys after incubation with preimmune
which roughly mirrored the decrease in cytosolic activityserum or PDE5 antiserum
(Table 2). Importantly, these pellets (that is, those gener-
PDE5 activity pmol/min/mg ated with the 1:10 dilution of the anti-PDE5 antibody)
Sham CBDL displayed both the highest concentration of PDE5 pro-
(N 5 5) (N 5 5)
tein (discussed previously in this article) and the highest
Supernatant levels of PDE5 activity (89.9 6 8.6 and 179.7 6 13.5 pmol/Basal 84.966.1 165.8612.0f
min/mg from sham and CBDL samples, respectively).Preimmune serum 82.265.3 172.269.3f
Anti-PDE5 antiserum These numbers are close to the basal activity initially
1:1000 49.968.1a 118.169.5a,f measured in cytosol. Immunoprecipitated PDE5 activity1:100 24.264.6a,b 50.768.2a,b,f
was inhibited in a concentration-dependent manner by1:10 10.962.7a,b 23.063.0a,b,f
Pellet both DMPPO and zaprinast (Table 2).
Preimmune serum 4.261.0 10.462.1f Data in Tables 1 and 2 indicate that DMPPO is 70 toAnti-PDE5 antiserum
100 times more potent than zaprinast in inhibition of1:1000 13.162.1c 30.263.5c,f
1:100 36.565.7c 96.669.8c,f PDE5 and that DMPPO is about 300 times more potent
1:10 89.968.6 179.7613.5f in inhibition of PDE5 than PDE1. To extend these con-1 DMPPO 3 nmol/L 61.465.2c 79.869.2c
clusions to the intact animal, we carried out VE in sham1 DMPPO 30 nmol/L 25.462.2c,d 31.963.8c,d
1 Zaprinast 0.1 mmol/L 68.366.4 109.368.3c,f and CBDL rats undergoing a continuous infusion of
1 Zaprinast 1 mmol/L 32.663.2c,e 46.963.4c,e,f DMPPO (0.2 mg/min) or zaprinast (10 mg/min) into the
Values are means 6 SE of PDE5 activity in supernatants and pellets of IMCD left renal artery. Intrarenal DMPPO infusion did notcytosol from five individual preparations incubated with preimmune serum or
PDE5 antiserum at the indicated dilutions followed by precipitation with protein materially affect baseline UNaV (Fig. 5). VE in sham rats
A-agarose as described in Methods. led to robust natriuresis from both DMPPO-infused lefta Significantly less than basal value, P , 0.05
b Significantly less than value with 1:1000 antibody dilution, P , 0.05 kidney and control right kidney. The right kidney of
c Significantly less than value at 1:10 antibody dilution, P , 0.05 CBDL rats showed blunted VE natriuresis; peak UNaVd Significantly less than value with 3 nmol/L DMPPO, P , 0.05
e Significantly less than value with 0.1 mmol/L zaprinast, P , 0.05 was only 2.1 6 0.41 mmol/min compared with 5.70 6
f Significantly greater than corresponding value in sham rats 1.07 mmol/min from the right kidney of sham rats (P ,
0.01). In marked contrast, peak UNaV from the DMPPO-
infused left kidney of these CBDL rats rose to 5.36 6
0.88 mmol/min, a value not statistically distinguishablerats and to 14% of basal in samples from CBDL rats
from the peak natriuresis from either right or left kidneys(Table 2). At the same time, there was a reciprocal in-
crease in enzyme activity recovered in the pellet con- of sham rats. These differences in response were paral-
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has not been established. Our earlier studies in rats with
proteinuric renal disease, due to adriamycin toxicity or
passive Heymann nephritis resulting from an injection of
Fx1A antiserum, led to the hypothesis that this resistance
could be due to heightened activity of PDE5 in renal
targets (for example, glomeruli, IMCD cells) for ANP
action. In the case of passive Heymann nephritis, relative
insensitivity to ANP was accompanied by increased
cGMP hydrolysis in IMCD cells versus controls [3]. Re-
sistance to ANP in both models was corrected both in
vitro and in vivo by the selective PDE5 inhibitor zaprinist
[2, 3]. A subsequent study [4] suggested that such a mech-
anism could also be operating in rats with renal ANP
resistance due to liver disease. Rats with CBDL demon-
strated ANP resistance similar to that seen in the protein-
uric models described previously in this article, and zapri-
nast, again, was able to restore renal ANP responsiveness
both in vitro and in vivo. The present data clearly indicate
that basal PDE5 activity of IMCD cells from CBDL rats
is significantly greater than that of IMCD cells from
sham rats. Kinetic analysis showed that increased PDE5
Fig. 5. Sodium excretion (UNaV) after volume expansion in sham and activity in these animals with liver disease is due to aCBDL rats undergoing continuous infusion of DMPPO, 0.2 mg/min
higher Vmax without a difference in Km. This increase in(0.5 nmol/min), into the left renal artery. The infusion did not influence
basal UNaV. At 30 minutes, normal saline in a volume equivalent to PDE5 activity was accompanied by a parallel increase
2% body weight was infused intravenously over 5 minutes as indicated
in the amount of enzyme protein, as shown by Westernby the horizontal bar, and urine was collected for another 30 minutes.
analysis, and treatment with an anti-PDE5 antiserumRight kidneys of CBDL rats exhibited blunted VE natriuresis; left
kidneys infused with DMPPO had a normal response. Symbols are: (d) produced a concentration-dependent reduction in cyto-
sham, left kidney; (s) sham, right kidney; (m) CBDL, left kidney; (n)
solic PDE activity. Blunted ANP responsiveness both inCBD., right kidney. Values are means 6 SE of measurements in six
vitro and in vivo was corrected by the highly selectiverats in each group. *Significantly greater than preinfusion values, P ,
0.01; †significant difference between right kidneys of CBDL rats and PDE5 inhibitor DMPPO as well as zaprinast. These re-
values in the other groups, P , 0.01.
sults therefore indicate that the renal resistance to ANP
in experimental liver disease caused by CBDL is due in
large measure to heightened activity of PDE5.
leled by similar differences in UcGMPV, a marker of the Other factors that could account for ANP resistance
renal actions of ANP, in both sham and CBDL rats can be ruled out from these and our earlier results [4].
(Table 3). Basal UcGMPV did not differ between sham The stimulus of VE caused plasma ANP concentration
and CBDL animals, but the increase after VE from non- to increase to the same extent in CBDL rats as in normals
infused right kidneys of CBDL animals was blunted com- so that relative ANP deficiency did not account for the
pared with sham animals or the DMPPO- or zaprinast- blunted ANP responsiveness. The demonstration of
infused left kidneys of CBDL rats (Table 3). Zaprinast blunted ANP-dependent cGMP accumulation in vitro
infusion into the left renal artery (10 mg/min) also nor- indicates that the resistance is not due to impaired access
malized VE natriuresis (data not shown), as we have of ANP to its binding sites in these cells. Although not
previously demonstrated [4]. However, the infusion rate measured in these experiments, our previous study
of zaprinast was more than 50 times greater than showed that there was no alteration in binding of
DMPPO on a molar basis. 125I-ANP to IMCD cells from kidneys of CBDL rats
Plasma ANP concentration was not significantly differ- [4]. Finally, the observation that the PDE5 inhibitors
ent between hydropenic sham and CBDL rats and rose
DMPPO and zaprinast restored VE natriuresis (that is,equivalently after VE in all groups whether infused intra-
ANP responsiveness) in vivo in parallel with increasedrenally with DMPPO or zaprinast (Fig. 6). Thus, the differ-
UcGMPV suggests strongly that a post-cGMP defect doesence in natriuresis after VE in these in vivo experiments
not account for ANP resistance in this model.is not caused by differences in ANP release after VE.
Characterization of the actions of DMPPO and zapri-
nast on PDE5 activity in IMCD cell homogenates indi-
DISCUSSION cated that these compounds inhibited enzyme activity
by increasing the apparent Km without effect on Vmax,The cellular basis for resistance to the natriuretic ac-
tions of ANP in states of abnormal sodium metabolism the result expected for competitive enzyme inhibition.
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Table 3. Urinary cyclic GMP excretion during infusion of DMPPO or zaprinast into the left renal artery before and after volume expansion
(VE) in sham and CBDL rats
Left kidney Right kidney
Control VE Control VE
DMPPO in left renal artery 0.5 nmol/min
Sham 11.1 62.3 55.467.0 10.862.6 49.066.4
P , 0.001 P , 0.01
CBDL 11.661.8 55.0614.5 8.463.9 25.160.9a
P , 0.05 P 5 0.021
Zaprinast in left renal artery 37 nmol/min
Sham 9.461.5 44.4611.8 12.764.7 57.4617.0
P 5 0.052 P 5 0.09
CBDL 5.662.1 55.5615.8 4.460.9 18.764.9b
P , 0.05 P 5 0.066
Values are means 6 SE of values during control and after volume expansion; units are pmol/min. P values refer to differences after VE compared to control
(paired t test); four animals were studied in each group.
a Significantly less than corresponding value from sham rats, P , 0.01
b Less than corresponding value from sham rats, P 5 0.071
enzyme inhibition was demonstrated between sham and
CBDL IMCD homogenates, together with the observed
differences in PDE5 protein levels in the two prepara-
tions, suggests that the increased PDE5 activity in CBDL
homogenates is not due to some modification of the
enzyme that might be expected to alter the nature of
inhibition by these compounds.
In kidney tissue, several other PDEs with an affinity
for cGMP have been identified. These include the cal-
cium-calmodulin dependent PDE1 [5–9] and the more
recently described PDE9 [10–12], PDE10 [13], and
PDE11 [14]. Zaprinast at relatively high concentrations
can inhibit the activity of these other members of the
PDE family [11, 13, 14, 16, 24]. We compared the effects
of DMPPO and zaprinast to inhibit PDE1 activity in
IMCD cell homogenates from sham rats. As indicated
in Table 1, each compound showed inhibitory activity
against this enzyme. However, in the case of DMPPO,
Ki and IC50 were roughly 300 times the values obtained
for PDE5. For zaprinast, activity against PDE1 occurred
Fig. 6. Plasma ANP concentration during hydropenia (control) and 30 at concentrations of only approximately 15 times those
minutes after VE in sham (h) or CBDL ( ) rats undergoing intrarenal
active against PDE5, confirming the greater selectivityinfusion of DMPPO or zaprinast. ANP concentration rose after VE
equivalently in all groups. *P , 0.01 vs. respective control group. and potency of DMPPO against PDE5 compared with
zaprinast [16] and raising the possibility that some or
all of the effects of zaprinast in vivo could result from
inhibition of PDE1. In the in vivo experiments, the con-The inhibition constant (Ki) and IC50 of DMPPO were
centration of DMPPO achieved in renal artery plasmafound to be in the nanomolar range. DMPPO corrected
would be predicted to be approximately 80 nmol/L ifthe blunted ANP-dependent cGMP accumulation of
renal plasma flow were 5 mL/min. Such a concentrationfreshly dispersed IMCD cells from kidneys of rats with
would be expected to cause trivial inhibition of PDE1,CBDL at a concentration of 1028 mol/L (Fig. 2), sug-
but near maximum inhibition of PDE5, providing furthergesting that the pharmacologic characterization of
evidence that correction of blunted VE natriuresis byDMPPO inhibition of PDE5 activity in cell cytosol corre-
DMPPO does not occur through inhibition of PDE1.lated well with its effects in intact cells. A similar conclu-
The study of Yamaki et al concluded that hydrolysis ofsion can be drawn for the action of zaprinast, although
both basal and ANP-stimulated cGMP in cultured ratit required a concentration roughly two orders of magni-
IMCD cells was mediated by PDE1 [6]. This conclusiontude higher than DMPPO to produce similar effects. The
fact that no major difference in the characteristics of was based on experiments using pharmacologic inhibi-
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tors of PDE1 versus PDE5. There is no immediate expla- nism of renal resistance to ANP. In agreement with this
nation for the difference in their results from those re- possibility, Kalinowski et al observed that normal rats
ported here using freshly dispersed IMCD cells other on a low-sodium diet exhibited renal resistance to in-
than to point out that cultured cells may exhibit a differ- fused ANP [27]. cGMP hydrolysis in kidney homoge-
ent phenotype compared to that seen in vivo. Additional nates was increased in these rats, and this increase was
experiments are required to clarify this point. inhibited by zaprinast. Thus, regulation of the renal ac-
Our studies do not completely rule out a role for the tions of ANP through changes in PDE5 activity may
other recently characterized PDE family members with be a normal component of the integrated response to
affinity for cGMP, namely, PDE9, PDE10, and PDE11. changes in extracellular fluid volume, which is also acti-
Inhibitor studies of PDE9 indicate that it is poorly inhib- vated in states of pathological sodium retention. In-
ited by the PDE5-selective inhibitors sildenafil (IC50 creased activity of zaprinast-inhibitable PDE has also
7 mmol/L) and zaprinast (IC50 ,30 mmol/L) [11, 12]. been observed in glomeruli of dogs with experimental
Since cGMP hydrolysis in our experiments was inhibited heart failure, another condition associated with renal
by DMPPO with an IC50 of 6.1 nmol/L (Table 1), a major ANP resistance [8]. On the other hand, other mecha-
role for PDE9 seems unlikely. The action of DMPPO nisms of ANP resistance are likely to exist. In rats with
against this enzyme has not yet been examined. Similarly, experimental heart failure [28, 29], as well as experimen-
inhibition studies of PDE10 and PDE11 indicate weaker tal diabetes [30], abnormalities in renal ANP binding
inhibition of these enzymes by PDE5-selective antago- have been identified. Nephrotic [31] and diabetic [32]
nists than PDE5 [13, 14], although, again, DMPPO has rats also exhibit extrarenal resistance to ANP in the form
not been studied. The immunoprecipitation studies, of a blunted increase in hematocrit in response to infused
however, make important roles for PDEs other than ANP. However, this extrarenal resistance is unlikely to
PDE5 very unlikely. The PDE5 antiserum reduced be due to increased PDE5 activity in the vasculature.
cGMP hydrolysis by approximately 85% in IMCD cyto- It is selective, occurring in rats with passive Heymann
sol from both sham and CBDL rat kidneys; residual nephritis but not adriamycin nephrosis and, in the for-
cGMP hydrolytic activity could reflect PDE5 not fully mer, is corrected by a subpressor infusion of angiotensin
precipitated at the 1:10 antibody dilution or hydrolysis by II [31]. Consequently, these observations suggest that
other PDEs. Whatever the basis for this residual activity, multiple mechanisms of renal and extrarenal ANP resis-
these observations suggest that catabolism of cGMP by tance may operate in the intact animal.
other PDEs could at most contribute no more than 15% In summary, renal resistance to the natriuretic effect
to the total. Identification of the renal cells that express of ANP in rats with experimental liver disease is accom-
these other PDEs and characterization of their pharma- panied by increased activity of PDE5 in IMCD cells, a
cologic properties and roles in hormone signaling are major site of ANP’s action to increase UNaV. That this
important issues for future study. increased enzyme activity is the major determinant of
The process by which CBDL leads to an increase in resistance is indicated by its correction, both in vitro and
PDE5 activity in renal IMCD cells is not known. Our in vivo, with selective inhibitors of the enzyme, and by
earlier study indicated that renal denervation improved immunoprecipitation of .85% of cGMP hydrolysis from
ANP resistance in rats with CBDL [4]. Renal denerva- IMCD cytosol with a specific antiserum against PDE5.
tion improves both blunted VE natriuresis and respon- Since sodium retention with the development of ascites
siveness to infused ANP in rats with CBDL [25, 26], and and edema is a hallmark of chronic liver disease, these
it is possible that heightened sympathetic efferent renal findings lead to the conclusion that abnormal sodium
nerve activity could constitute the signal responsible for metabolism in cirrhosis may be related to renal resistance
increased PDE5 activity in this model. Consistent with to ANP, which, in turn, is caused by heightened PDE5
this, we have determined in preliminary experiments that activity. This mechanism may also underlie the ANP resis-
renal denervation reduces PDE5 activity in IMCD cell tance of nephrotic syndrome and other settings of dimin-
homogenates from kidneys of CBDL rats (abstract; Lee ished extracellular fluid volume, effective or real. Further
et al, J Am Soc Nephrol 6:799, 1995). However, further understanding of the pathways leading to this heightened
experiments are required to determine whether in- enzyme activity should provide valuable insight into this
creased efferent nerve activity is the mechanism underly- and other states of pathological sodium retention, and
ing the increase in PDE5 activity that we have demon- suggest novel approaches to their treatment.
strated in CBDL rats.
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